Toxoplasmosis retinochoroiditis after photodynamic therapy and intravitreal triamcinolone for a supposed choroidal neovascularization: A case report

Arquivos Brasileiros de Oftalmologia

Volumn 70, Issue 1, 2007, Pages 157-160

  Nóbrega, Mário Junqueira ^a,b,c,d   Rosa, Evandro Luís ^c  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF JOINVILLE REGION   (Brazil)

^c Hospital de Olhos Sadalla Amin Ghanem   (Brazil)

^d NONE   (Brazil)

Author keywords

Case reports publication type ; Choroidal neovascularization; Injections; Toxoplasmosis, ocular; Triamcinolone adverse effects; Uveitis; Vitreous body

Indexed keywords

EID: 34147115748     PISSN: 00042749     EISSN: 16782925     Source Type: Journal    
DOI: 10.1590/S0004-27492007000100030     Document Type: Article

References (13)

1. Bressler NM. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2. Arch Ophthalmol. 2001;119 (2):198-207. Comment in: Arch Ophthalmol. 2005;123(9):1283-5.
2. Verteporfin in Photodynamic Therapy Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization-verteporfin in photodynamic therapy report 2. Am J Ophthalmol. 2001;131(5):541-60. Comment in: Am J Ophthalmol. 2002:133(2):294-6. Am J Ophthalmol. 2002;133(1):168-9. Am J Ophthalmol 2002;133(6):857; author reply 857-9.
3. Spaide RF, Sorenson J, Maranan L. Combined photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide for choroidal neovascularization. Ophthalmology. 2003;110(8):1517-25.
4. Rechtman E, Danis RP, Pratt LM, Harris A. Intravitreal triamcinolone with photodynamic therapy for subfoveal choroidal neovascularisation in age related macular degeneration. Br J Ophthalmol. 2004;88(3):344-7.
5. Spaide RF, Sorenson J, Maranan L. Photodynamic therapy with verteporfin combined with intravitreal injection of triamcinolone acetonide for choroidal neovascularization. Ophthalmology. 2005;112(2):301-4.
6. Jonas JB, Kreissig I, Kamppeter B, Degenring RF. [Intravitreal triamcinolone acetonide for the treatment of intraocular edematous and neovascular diseases] Ophthalmologe. 2004 Feb;101(2):113-20. German.
7. Andrade REA, Muccioli C, Farah ME. Injeção intravítrea de triancinolona no tratamento da síndrome de Vogt-Koyanagi-Harada. Arq Bras Oftalmol. 2004; 67(3):401-6.
8. Campos VE, Maia A, Muccioli C, Belfort R Jr. Pseudohypopyon immediately after intravitreal injection of triamcinolone acetonide - case reports. Arq Bras Oftalmol. 2005;68(2):251-2.
9. Jonas JB, Kreissig I. Degenring R. Intraocular pressure after intravitreal injection of triamcinolone acetonide. Br J Ophthalmol. 2003;87(1):24-7. Comment in: Br J Ophthalmol. 2004;88(4):598; author reply 598.
10. Friedman DS, O'Colmain BJ, Muñoz B, Tomany SC, McCarty C, de Jong PT, et al. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol. 2004:122(4):564-72. Comment in: JAMA, 2004;291(15):1900-1.
11. Santos LPF, Diniz JR, Leão ACS, Sena MF. Degeneração macular relacionada à idade: prevalência e fatores de risco em dois centros oftalmológicos de referência em Pernambuco. Arq Bras Oftalmol. 2005:68(2):229-33.
12. Loewenstein A, Bressler NM. Neovascular (exudative) age-related macular degeneration. In: Guyer DR, Yannuzzi LA, Chang S, Shields JA, Green WR. editors. Retina-vitreous-macula. Philadelplaia: W. B. Saunders; 1999. p.94-121.
13. Da Mata AP, Oréfice F. Toxoplasmosis. In: Foster CS, Vitale AT, editors. Diagnosis and treatment of uveitis. Philadelphia: W. B. Saunders; 2002. p.385-410.